ADLM 2024

Result precision on the new Cobas Pro integrated solutions Cobas ISE neo and Cobas c 703 analytical units under routine-like conditions across two sites in Europe

In this study the precision of the new Cobas® Pro integrated solutions Cobas ISE neo and Cobas c 703 analytical units was measured under intended use conditions in a routine simulation setting. The findings from this multicenter study demonstrate that the new ISE neo and c 703 analytical units show consistent results over a prolonged period, with most CVs in this setting below 0.9%. Moreover, successful integration of the new analytical units into the Pro integrated solutions, with seamless interaction of existing and analytical units under stressed conditions, is shown.

CLSI-based result precision on the Cobas ISE neo and Cobas c 703 analytical units across two sites in Europe

In this study the novel Cobas® Pro integrated solutions analytical units, the Cobas ISE neo and the Cobas c 703 analytical units, were assessed at two sites in Europe. Both analytical units demonstrated robust precision, comparable with the existing Pro integrated solutions analytical units, over a prolonged period.

Clinical Performance Evaluation of the Polymerase Chain Reaction (PCR)-Based Cobas CT/NG/MG Test for Use on the Cobas Liat System in a Clinical Laboratory Setting and Point-of-Care (POC) Location

This clinical performance evaluation of the Cobas® Liat CT/NG/MG nucleic acid test, conducted in diverse clinical settings across the United States, aimed to address the challenges posed by sexually transmitted infections (STIs) such as Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG). The results highlighted the good clinical performance of the Cobas Liat CT/NG/MG test, particularly in providing rapid lab-quality testing at the point of care for both self- and clinician-collected samples. In clinical settings, the test was identified as a tool to provide rapid testing for CT, NG, and MG infections, offering the potential to minimize the need for empiric treatment. This presents an opportunity to improve clinical outcomes for patients and enhance antimicrobial stewardship. An audio accompaniment to this poster was made available to online participants ADLM 2024.

External site

ADLM 2024